» Articles » PMID: 38700658

Long-term Symptoms After SARS-CoV-2 Infection in a Cohort of People Living with HIV

Overview
Journal Infection
Date 2024 May 3
PMID 38700658
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about the impact of HIV infection on the risk of post-COVID-19 conditions (PCCs) onset. We aim to assess the incidence of PCC in PLWH and the factors associated with its occurrence.

Methods: We performed a retrospective, observational study including all PLWH > 18 years registered in the Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, and viro-immunological parameters from February 2020 until May 2022. Persistence of self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, and neuro-behavioral symptoms) was evaluated after 3 months by a telephone-administered questionnaire. We estimated the associations between all variables and outcomes through univariate and multivariable logistic models.

Results: In the study period, 653 PLWH were diagnosed with SARS-CoV-2 infection (17.1%). We observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, and 3 (0.5%) deaths. We interviewed 510/653 PLWH (78%), and 178 (PCCs prevalence 34.9%; CI 95% 30.7-39.2) reported persistent symptoms. Asthenia/fatigue was the most reported symptom (60/178), followed by muscular pain (54/178). In the multivariate regression model, there was a lower risk of PCCs in males respect to females (adjusted OR = 0.64; CI 95% 0.99-3.66), while hospitalization during acute infection was associated with an increased the risk of PCCs (adjusted OR = 1.9; CI 95% 0.99-3.66). Notably, no viro-immunological variable modified the PCCs risk onset.

Conclusions: Our study highlights a substantial prevalence of PCCs among PLWH, three months post-SARS-CoV-2 infection, independent of viro-immunological features or vaccination status.

Citing Articles

Prevalence of post-acute sequelae of SARS-CoV-2 infection in people living with HIV: a systematic review with meta-analysis.

Pouliopoulou D, Billias N, MacDermid J, Miller E, OBrien K, Quinn K EClinicalMedicine. 2025; 79():102993.

PMID: 39802304 PMC: 11721256. DOI: 10.1016/j.eclinm.2024.102993.

References
1.
Larsen N, Stiles L, Miglis M . Preparing for the long-haul: Autonomic complications of COVID-19. Auton Neurosci. 2021; 235:102841. PMC: 8254396. DOI: 10.1016/j.autneu.2021.102841. View

2.
Hoft M, Burgers W, Riou C . The immune response to SARS-CoV-2 in people with HIV. Cell Mol Immunol. 2023; 21(2):184-196. PMC: 10806256. DOI: 10.1038/s41423-023-01087-w. View

3.
Kahlert C, Strahm C, Gusewell S, Cusini A, Brucher A, Goppel S . Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clin Infect Dis. 2023; 77(2):194-202. PMC: 10371307. DOI: 10.1093/cid/ciad143. View

4.
Kamanzi P, Mulundu G, Mutale K, Mumba C, Ngalamika O . HIV and inflammatory markers are associated with persistent COVID-19 symptoms. Immun Inflamm Dis. 2023; 11(5):e859. PMC: 10165949. DOI: 10.1002/iid3.859. View

5.
Tiecco G, Storti S, Degli Antoni M, Foca E, Castelli F, Quiros-Roldan E . Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. Int J Mol Sci. 2022; 23(4). PMC: 8876558. DOI: 10.3390/ijms23041987. View